There is a paucity of information with regard to the prevalence and clinical sequelae of these drugs. The aim of this study was to detect NPS in patients presenting to the emergency department with suspected toxicological ingestion.
Patients and methods The prospective study was performed in a large emergency department in the UK. During a 3-month period 80 patients were identified by clinicians as having potentially ingested a toxicological agent. Urine samples were analysed using liquid chromatography high-resolution mass spectrometry, and basic clinical data was gathered.
Results Eighty patients with a history of illicit or recreational drug consumption had urine screenings performed. Forty-nine per cent (39) of the patients undergoing a screen had more than one illicit substance detected. Twenty per cent (16) of the patients tested positive for at least one NPS.
Conclusion Almost half of the presented patients revealed ingestion of multiple substances, which correlated poorly with self-reporting of patients. Developing enhanced strategies to monitor evolving drug trends is crucial to the ability of clinicians to deliver care to this challenging group of patients. European Journal of Emergency Medicine 24:126-129 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Attendances in emergency departments (EDs) due to the sequela of the effects of drugs of abuse creates a significant burden [1] [2] [3] . Drug abuse became regarded as an epidemic problem with the rise of heroin in the 1960s [4] . Recreational drug use is more prevalent among young adults and is associated with significant short-term and long-term health implications [5, 6] . Novel psychoactive substance (NPS) is a generic term used to describe substances that mimic the effects of traditional illicit drugs. These psychoactive substances are newly available and, although not necessarily prohibited, pose a public health threat comparable to that of traditional illicit substances [7] .
There has been a steady rise in the number of synthetic and plant-based psychoactive substances, with an exponential growth in the production and distribution of such drugs [8] [9] [10] . The unknown safety profile, active ingredients and quantity increase the risk of overdose and serious clinical consequences [11, 12] . There remains inconsistent sampling and reporting of attendances to the ED following ingestion of NPS and of the clinical manifestations [13] . Proliferation of NPS abuse has been facilitated by inconsistent legislation allowing uncontrolled access to substances. The ability to evade detection by standard toxicological screens allied with easy availability in shops and on the Internet has made these drugs increasingly attractive recreational substances [14] . Developing analytical profiling of agents and reference standards is an area of considerable ongoing work [15, 16] .
Surveillance of drug abuse patterns is crucial to developing strategies to direct both clinical-based and community-based interventions [17] . Creating a detailed understanding of current trends is challenging in the face of constantly evolving habits [18, 19] . Although population surveys provide useful information, the illicit nature of drug abuse and the reliability of respondents pose problems [20, 21] .
The clinical challenge is to safely treat patients who have ingested unknown substances, which is achieved by responding to the toxidrome on presentation [22] . The paucity of analytical confirmation of hazardous substances prevents clinicians from effectively managing these patients [23] . Identification of these novel substances enables tracking of use, effects from ingestion of these novel drugs and also the changing patterns of abuse [24, 25] . Coingestion of synergistic or antagonistic substances can lead to diagnostic and treatment challenges [26] .
Before this surveillance study, urine samples were sent for analysis using a commercially available testing kit for traditional substances of abuse (Alere Inc., San Diego, California, USA). It was increasingly recognized that this screen did not encompass the range of substances that were self-reported or corresponded to the toxidrome of the patient [21] . Evolution of drug behaviours within the local population had extended beyond the testing capabilities of the ED and local laboratory provision.
Patients and methods

Patients and sampling
This was a single-center prospective observational study. Glasgow Royal Infirmary is a large inner city ED with ∼ 86 000 attendances each year. During a 3-month period (1 May 2014 to 29 July 2014), data were collected of all patients who attended the department and who were identified by the treating clinicians based on their history or clinical suspicion as attending because of ingestion of NPS, for which a urine sample was collected. Patients were excluded if they were younger than 16 years of age.
Data were collected using a standardized proforma. Patient's data were anonymized and linked to presentation by a unique code number. Urine samples were stored in additivefree containers in a laboratory refrigerator until testing within a week of collection. Data analysis was performed using Microsoft Excel (2011; Microsoft Corporation, Redmond, Washington, USA).
Urine samples were extracted using a simple liquid-liquid procedure with MTBE and Tris buffer and analysed using liquid chromatography high resolution mass spectrometry. A Bruker MicrOTOF-Q (Bruker, Billerica, Massachusetts, USA) with an Agilent 1260 Infinity (Agilent, Santa Clara, USA) HPLC was used for analysis. Identification was achieved by matching retention time, mass (four decimal places) and isotope pattern.
Ethics
Ethics was sought and granted from NHS GG&C Ethics as a service evaluation. Consent was waived for the study as this was considered a service development study as urine samples are sent for a toxicology screen as a standard of care.
Results
Eighty patients with suspected ingestion of recreational drugs presenting at the ED had urine screenings performed. For the purposes of the study, an NPS was defined as a drug acting on the central nervous system, out-with those traditionally recognized as recreational drugs. The additional NPS tested for included: methoxetamine, etizolam, methlyenedioxyaminoindane (MDAI), piperazines [including 3-trifluoromethylphenylpiperazine (TFMPP)], paramethoxyamphetamine (PMA) and any synthetic cathinones. Case histories were not available for five patients; hence, demographic data are not available.
The range of drugs detected and respective frequencies are shown in Table 1 . There was a male predominance; 54 men (aged 17-55 years) compared with 21 women (aged 16-47 years). The source of referral for patients was ambulance [49% (37)], self-referral [19% (14) ] and police [32% (24) ]. Thirty-six per cent (27) of the patients required admission, with the remaining 64% (48) discharged directly from the ED. Twenty per cent (16) of the patients tested positive for at least one NPS.
The total number of nonprescribed drugs detected in patients is reported in Fig. 1 . Forty-nine per cent (39/80) of the patients undergoing a screen had more than one illicit substance detected. 
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Only five patients reported consumption of an NPS; the results of their screenings are shown in Table 2 . Table 3 lists the patients who tested positive for NPS agents and their reported ingestions. Eleven patients were unable to give a history of ingestion because of their medical condition on arrival.
Discussion
The study reports the urine screening results of those patients who reported drug consumption for recreational purposes, or who presented with a clinical toxidrome suggestive of acute drug intoxication. The main objective was the detection of NPS in patients presenting to EDs; in our study 16 patients had NPS agents detected, of which only five patients reported consumption of these drugs. It is unclear whether there was deliberate misreporting by patients or whether patients were not aware that they had ingested an NPS.
A selection of NPS agents were detected, predominantly the ecstasy MDMA 'mimics', such as PMA/PMMA, MDAI, and TFMPP; only one patient gave a history of ecstasy consumption and tested positive for one of these compounds. From the NPS detected, only MDAI and etizolam are not currently regulated by the Misuse of Drugs Act in the UK. Only five patients reported taking an NPS (referred to as a 'legal high' in their own terms); one patient tested positive for PMA, whereas the rest were negative for NPS; however, this may have been a synthetic cannabinoid agent that had not been tested for in this study.
Of interest was the detection of amitriptyline and mirtazapine in our patient population; all the amitriptyline detected was present in patients also testing positive for methadone, diazepam, and other illicit substances. Only one patient reported the ingestion of amitriptyline, none reported the use of mirtazapine; abuse of amitriptyline by patients on methadone substitution therapy has been recognized since 1978 [1] ; however, the nonprescription use of mirtazapine has not been reported in the literature.
Etizolam, a thienodiazepine, is not currently regulated in the UK; as with amitriptyline, it was only detected in patients who tested positive for other illicit drugs. No patients reported the intentional consumption of etizolam and only two patients reported a history of consumption of benzodiazepines out of the seven who tested positive for the drug.
Limitations
Our study had several limitations. First, it was performed at a single institution and limited to patients whom individual clinicians had identified as having ingested a toxicological agent. Retrospective review of triage notes did not reveal any clearly missed patients but relied upon individual clinician's identification and subsequent inclusion in the study. Synthetic cannabinoids were not included in this study but will be included in future studies. Because of the lack of reference standards, some novel agents may not have been identified. There is the potential for degradation of metabolites and no quantitative work was performed on the analytes. In addition, 24 patients who were enrolled in the study had negative samples for which there are a number of explanations: the patient had not ingested the substance; we did not test for the analyte; an error had occurred during storage/ sampling; or the patient had been incorrectly enrolled; or extensive metabolism led to no parent drug in the urine.
Future
The purpose of this study was to evaluate the current toxicology screening against the potential range of substances ingested presenting in a large city ED. Sharing of the findings within the ED and other agencies raised the awareness of these varied and potentially hazardous substances. Development of point of care testing to enable rapid identification during presentation would aid treatment and risk stratification. Incorporating testing for NPS in postmortems and development of new standards for testing may facilitate greater recognition of the contribution of these substances in forensic cases and inform future drug surveillance and regulation strategies.
Conclusion
Only a small percentage of samples tested positive for NPS. Most samples were positive for more commonly encountered drugs of abuse. It is important to understand the range of drugs that are affecting our local population. The extent of polyingestion has significant implications for management of these patients within the ED. The poor correlation between reporting and detection emphasizes the need for clinicians to have a high degree of suspicion and treat the presenting toxicological syndrome. This may, of course, represent a lack of knowledge by patients about the substances they are ingesting. The combination of both illicit drugs, newer drugs of variable legal status and those previously unconsidered drugs represents a substantial challenge to the treating physician. It is apparent from the study that NPS use is prevalent in a range of age groups and social backgrounds. By identifying the individual drugs and trends that are prevalent, we can direct resources into understanding their effects and implications on this challenging group of patients.
